McKesson OKs $141M Investor Deal Over Generic Price-Fixing
McKesson will pay shareholders $141 million to resolve class action claims in federal court in California over its allegedly false assertions about generic drug prices that plaintiffs traced to a generic-drug...To view the full article, register now.
Already a subscriber? Click here to view full article